W Sievert

Summary

Affiliation: Monash University
Country: Australia

Publications

  1. ncbi request reprint Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major
    William Sievert
    Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
    Am J Gastroenterol 97:982-7. 2002
  2. ncbi request reprint Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone
    W Sievert
    Department of Medicine, Monash Medical Centre, Monash University, Melbourne, Clayton, Vic, Australia
    Aliment Pharmacol Ther 17:1197-204. 2003
  3. ncbi request reprint Management issues in chronic viral hepatitis: hepatitis C
    William Sievert
    Monash University Department of Medicine, Monash Medical Centre, 246 Clayton Road, Melbourne 3168, Australia
    J Gastroenterol Hepatol 17:415-22. 2002
  4. doi request reprint Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial
    Stuart K Roberts
    The Alfred, Melbourne, Australia
    Hepatology 50:1045-55. 2009
  5. ncbi request reprint Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome
    Anouk T Dev
    Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
    Hepatology 36:1259-65. 2002
  6. doi request reprint Transplantation of human amnion epithelial cells reduces hepatic fibrosis in immunocompetent CCl₄-treated mice
    Ursula Manuelpillai
    Centre for Reproduction and Development, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia
    Cell Transplant 19:1157-68. 2010
  7. ncbi request reprint A survey of Australian general practice management of hepatitis C-infected patients from non-English-speaking backgrounds
    Anouk Dev
    Monash University Department of Medicine, Monash Medical Center, Melbourne, Victoria, Australia
    J Gastroenterol Hepatol 17:295-300. 2002
  8. ncbi request reprint Antiviral therapy for chronic hepatitis C
    William Sievert
    Departments of Medicine and Gastroenterology, Monash University, Monash Medical Centre, Victoria
    Aust Fam Physician 32:826-32. 2003
  9. ncbi request reprint Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection
    S Pianko
    Monash University, Department of Medicine and Gastroenterology Unit, Monash Medical Centre, Melbourne, Australia
    J Viral Hepat 8:406-13. 2001
  10. ncbi request reprint Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition
    Anouk Dev
    Monash University Department of Medicine and Department of Gastroenterology, Monash Medical Center, Melbourne, Victoria, Australia
    J Gastroenterol Hepatol 19:792-8. 2004

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major
    William Sievert
    Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
    Am J Gastroenterol 97:982-7. 2002
    ..The aim of this study was to evaluate the effect of hepatic iron concentration (HIC) on response to interferon monotherapy in patients with massive hepatic iron overload...
  2. ncbi request reprint Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone
    W Sievert
    Department of Medicine, Monash Medical Centre, Monash University, Melbourne, Clayton, Vic, Australia
    Aliment Pharmacol Ther 17:1197-204. 2003
    ..High-dose induction interferon may enhance early viral clearance, whilst ribavirin reduces relapse; in combination, they may improve sustained virological response rates...
  3. ncbi request reprint Management issues in chronic viral hepatitis: hepatitis C
    William Sievert
    Monash University Department of Medicine, Monash Medical Centre, 246 Clayton Road, Melbourne 3168, Australia
    J Gastroenterol Hepatol 17:415-22. 2002
    ..Current data strongly support the concept that SVR in HCV infection (or treatment-induced latency) provides a cure in terms of its beneficial effects on quality of life and sustained amelioration of liver injury...
  4. doi request reprint Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial
    Stuart K Roberts
    The Alfred, Melbourne, Australia
    Hepatology 50:1045-55. 2009
    ..The high SVR rates in patients with minimal fibrosis highlight the benefit of early treatment in patients with hepatitis C virus genotype 1...
  5. ncbi request reprint Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome
    Anouk T Dev
    Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia
    Hepatology 36:1259-65. 2002
    ..This study also supports the concept that race and ethnicity are important determinants of treatment outcome in HCV infected patients...
  6. doi request reprint Transplantation of human amnion epithelial cells reduces hepatic fibrosis in immunocompetent CCl₄-treated mice
    Ursula Manuelpillai
    Centre for Reproduction and Development, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia
    Cell Transplant 19:1157-68. 2010
    ..hAEC transplantation into immunocompetent mice leads to cell engraftment, reduced hepatocyte apoptosis, and decreased hepatic inflammation and fibrosis...
  7. ncbi request reprint A survey of Australian general practice management of hepatitis C-infected patients from non-English-speaking backgrounds
    Anouk Dev
    Monash University Department of Medicine, Monash Medical Center, Melbourne, Victoria, Australia
    J Gastroenterol Hepatol 17:295-300. 2002
    ..General practitioners, who are often the first health professionals consulted, need to be aware of risk factors and complications associated with hepatitis C in this group...
  8. ncbi request reprint Antiviral therapy for chronic hepatitis C
    William Sievert
    Departments of Medicine and Gastroenterology, Monash University, Monash Medical Centre, Victoria
    Aust Fam Physician 32:826-32. 2003
  9. ncbi request reprint Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection
    S Pianko
    Monash University, Department of Medicine and Gastroenterology Unit, Monash Medical Centre, Melbourne, Australia
    J Viral Hepat 8:406-13. 2001
    ..The correlation between Fas expression and TUNEL supports the hypothesis that the Fas-Fas ligand interaction is the major mechanism for HCV-induced hepatocyte apoptosis...
  10. ncbi request reprint Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition
    Anouk Dev
    Monash University Department of Medicine and Department of Gastroenterology, Monash Medical Center, Melbourne, Victoria, Australia
    J Gastroenterol Hepatol 19:792-8. 2004
    ..Accurate risk factor assessment is essential for education targeted at risk reduction in culturally diverse populations...
  11. ncbi request reprint Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis
    S Patella
    Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, Monash University, Clayton, Victoria, Australia
    J Hepatol 34:576-83. 2001
    ..Dysregulation of the activin/follistatin axis may be linked to hepatitis B replication but does not correlate with hepatocyte apoptosis...
  12. doi request reprint Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat
    John S Lubel
    Department of Medicine, The University of Melbourne, Austin Health and Northern Health, Vic, Australia
    Clin Sci (Lond) 117:375-86. 2009
    ..In conclusion, Ang-(1-7) is up-regulated in human liver disease and has antifibrotic actions in a rat model of cirrhosis. The ACE2/Ang-(1-7)/mas receptor axis represents a potential target for antifibrotic therapy in humans...
  13. ncbi request reprint Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection
    Mark Danta
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW
    Med J Aust 177:240-5. 2002
    ..To determine factors associated with hepatic fibrosis development in people with chronic hepatitis C virus (HCV) infection...
  14. ncbi request reprint Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial
    Henry L Y Chan
    The Chinese University of Hong Kong, Shatin, Hong Kong, China
    Ann Intern Med 147:745-54. 2007
    ..The efficacy of nucleoside and nucleotide analogues for hepatitis B has been linked to the magnitude and durability of hepatitis B virus (HBV) suppression...
  15. doi request reprint Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Hopital Beaujon, Paris, France
    Hepatology 48:750-8. 2008
    ..Adefovir resistance mutations A181V or N236T developed in 13 LTSES patients; the first observation was at study week 195. There were no serious adverse events related to ADV...
  16. ncbi request reprint Serum alanine aminotransferase levels and the detection of hepatitis C virus (HCV) in chronic HCV infections
    Heath A Kelly
    Med J Aust 176:139. 2002
  17. ncbi request reprint Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481, and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 348:808-16. 2003
    ..In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains...